Breaking News, Financial News

Financial Report: Roche 1Q

Pharmaceutical revenues were flat at $8.1 billion (up 8% in local currencies) with Europe/ROW sales down 8%, U.S. sales up 1%, and Japan sales up 58%.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Roche 1Q 1Q Revenues: $10.1 billion (-1%) 1Q Earnings: n/a* Comments: Pharmaceutical revenues were flat at $8.1 billion (up 8% in local currencies) with Europe/ROW sales down 8%, U.S. sales up 1%, and Japan sales up 58%. Sales drivers were Avastin, Herceptin, Tamiflu, MabThera/Rituxan and Lucentis. In the U.S., growth of key products offset lower sales of Tamiflu. Sales by Chugai in Japan increased due to Tamiflu, anticancer medicines, and Actemra, which was approved for RA in Japan in ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters